NTLX (NTLX) News
Follow NTLX (NTLX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
(TheNewswire)The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as d
NEWS | Sep 23, 2026, 12:16 PM UTC
L
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disordersVancouver, Canada, Sept. 23, 202
NEWS | Sep 23, 2026, 12:01 PM UTC
M
SciSparc unit NeuroThera pursues FDA orphan drug designation for adult Tourette
NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA orphan drug designation for an adult Tourette Syndrome treatment and has engaged RK Strategies for government and public affairs support.
GEOPOLITICS | Sep 02, 2026, 12:11 PM UTC
L
SciSparc unit NeuroThera Labs reports SCI-210 autism trial enrollment momentum
SciSparc subsidiary NeuroThera Labs said it has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
EQUITY | Aug 31, 2026, 08:07 PM UTC
L
NeuroThera Labs touts enrollment momentum in SCI-210 autism trial
NeuroThera Labs said it has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
EQUITY | Aug 31, 2026, 08:00 PM UTC
L
Neurothera Labs announces share consolidation
Neurothera Labs Inc. announced a share consolidation.
EQUITY | Aug 28, 2026, 09:05 PM UTC
L
NeuroThera Labs Engages Dr. Reuter Investor Relations
NeuroThera Labs Engages Dr. Reuter Investor Relations
EQUITY | Aug 27, 2026, 12:01 PM UTC